Navigation Links
Biodel Inc. to Present at the BioCentury Future Leaders Conference on March 27th, 2008
Date:3/20/2008

DANBURY, Conn., March 20 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that Gerard Michel, Chief Financial Officer, Vice President of Corporate Development and Treasurer of Biodel, will present a corporate update at the BioCentury Future Leaders Conference on Thursday, March 27, 2008 at 3:00 p.m. Eastern Time. The conference will be held at the Millennium Broadway Hotel and Conference Center in New York City.

Interested parties may access a link to a live webcast of the corporate presentation in the investor relations section of Biodel's website at http://www.biodel.com. An archive of the presentation will be available at the same location.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA- approved peptide drugs. The Company's lead product candidate, VIAject(TM), is an ultra rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in the Phase I stage of clinical testing, and two pre-clinical osteoporosis product candidates. For further information regarding Biodel, please visit the Company's website at http://www.biodel.com.

BIOD-G


'/>"/>
SOURCE Biodel Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results
2. Biodel Inc. to Announce First Quarter Fiscal Year 2008 Financial Results on February 14, 2008
3. Biodel Inc. Announces Pricing of Public Offering
4. Biodel to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on December 11, 2007
5. Brian J.G. Pereira, M.D. Joins Biodels Board of Directors
6. Biodel Inc. to Present at Natixis Bleichroeder Hidden Gems Conference on October 8, 2007
7. Biodel Inc. to Present at BIO InvestorForum 2007 Conference on October 11, 2007
8. Biodel to Amend June 30, 2007 10-Q to Correct Non-Cash Share-Based Compensation Expense
9. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
10. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
11. Evotec AG: Fiscal Year 2007 Results Presentation on March 28, 2008 Live on the Internet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen Matloff, president and ... Council (CTC) as a 2017 Women of Innovation® finalist. Matloff will be among ... Dinner. , The dinner recognizes women accomplished in science, technology, engineering and math ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company ... A financing and note conversion to commercialize its Cool ... is focused on developing products that are simultaneously profitable ... million in the last 18 months. This latest round ... Bridge Venture Partners. The company,s primary ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... regeneration from small lab samples to full-size tissues, bones, even whole organs to ... vascular system that delivers blood deep into the developing tissue. , Current ...
(Date:3/22/2017)... JERUSALEM , March 22, 2017 ... ( www.oramed.com ), ... of oral drug delivery systems, announced today that ... Officer, will deliver a presentation titled, "Oral Insulin ... upcoming Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics ...
Breaking Biology Technology:
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber Ventures ... it has led a $3.5 million investment in  Polarity ... Strategic Cyber Ventures is DC based and is led ... Hank Thomas . Ron Gula , also a ... also participated in this series A round of funding. ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
Breaking Biology News(10 mins):